Richard Bregman, MD
Sleep Medicine · Tulsa, OKNPI 1285640771
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,555 of the $1,815 with a category attached, or 85.7%. Jazz Pharmaceuticals Inc. accounts for 60.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $669 and has fallen 59.4% since, to $271 in 2024.
Across 85 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$1K
- Harmony Biosciences LLC$342
- Eisai Inc.$88
- Axsome Therapeutics, Inc.$71
- ZOLL Respicardia, Inc.$71
- Avadel CNS Pharmaceuticals, LLC$61
- plus $80 from 4 others
What the payments were for
- Food & beverage$1,55586%
- Education$26014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 49 | $1,102 |
| Harmony Biosciences LLC | 16 | $342 |
| Eisai Inc. | 6 | $88 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| ZOLL Respicardia, Inc. | 4 | $71 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $61 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
How this compares
$1,815 in reported general payments places this provider in the 55th percentile of 20 sleep medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 13 | $1,299 |
| Zaleplon | 38 | $112 |
| Gabapentin | 16 | $98 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in Tulsa
- Michael NewnamTulsa$284K
- Marilyn CulpTulsa$4K
- Amritanshu SinghTulsa$3K
- Keziah AibangbeeTulsa$2K
- Christian NguyenTulsa$1K
- Jana LovelessTulsa$250
- Liphard DsouzaTulsa$156
- Tanzeel AwadallaTulsa$53
- Viral DoshiOklahoma City$56K
- Asim MaqsoodOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.